000			02302cam a22004694a 4500
001			P 1545
005			20140212102809.0
008			070309s2008 flua b 001 0 eng
010			_a 2007010012
015			_aGBA6A2532 _2bnb
016	7		_a013618958 _2Uk
016	7		_a101301450 _2DNLM
020			_a0849390060 (hbk. : alk. paper)
020			_a9780849390067 (hbk. : alk. paper)
035			_a(OCoLC)76936122
035			_a(OCoLC)ocm76936122
040			_aDNLM/DLC _cDLC _dDLC
042			_apcc
050	0	0	_aRS403 _b.C43-2008
060	1	0	_aQV 744 _bC5173 2008
082	0	0	_a615/.19 _222
245	0	0	_aChemistry and molecular aspects of drug design and action / _c[edited by] E.A. Rekka, P.N. Kourounakis.
260			_aBoca Raton : _bCRC Press/Taylor & Francis, _cc2008.
300			_axxii, 356 p. : _bill. ; _c25 cm.
504			_aIncludes bibliographical references and index.
505			_aInflammatory mechanisms in Alzheimer's disease and other neurodegenerative disorders / Joseph Rogers ... [et al.] -- Treatment development strategies for Alzheimer's disease / Ernst W�ulfert -- Lipoprotein-associated phospholipase Ab2{e
505			_aThiocarboxanilides : a new class of nonnucleoside reverse transcriptase inhibitors (NNRTIs) with great potential for the treatment of human immunodeficiency virus type 1 (HIV-1) infections / E. De Clercq, A. Karlsson, and J. Balzarini -- Histami
650		0	_aDrugs _xDesign.
650		0	_aPharmaceutical chemistry.
650	1	2	_aChemistry, Pharmaceutical.
650	2	2	_aDrug Design.
650	2	2	_aPharmacologic Actions.
700	1		_aKourounakis, P. N.
700	1		_aRekka, E. A.
856	4	1	_3Table of contents only _uhttp://www.loc.gov/catdir/toc/ecip0712/2007010012.html
856	4	2	_3Publisher description _uhttp://www.loc.gov/catdir/enhancements/fy0710/2007010012-d.html
906			_a7 _bcbc _corignew _d1 _eecip _f20 _gy-gencatlg
925	0		_aacquire _b2 shelf copies _xpolicydefault, Sel/sdb 2008-10-20
925	1		_aacquire _b1 shelf copy _xpolicy default
942			_cBK
955			_djc18 2007-03-12 _ejc18 2007-03-12 to Dewey _fjx13 2008-06-18 Z-CipVer _gjx13 2008-06-18 to BCCD
999			_c6608 _d6608